Canopy Biosciences aims to accelerate the commercialization of life science reagent tools and services through in-licensing.
Canopy Biosciences is biotechnological company that provides products and services for gene editing and personalized medicine. The gene editing technology is called TUNR and targets translation elongation by inserting polyA tracks into targeted coding regions of the genome. This change then decreases the levels of mRNA transcribed from the gene and therefore suppresses protein expression. It was initially developed by Professor Sergej Djuranovic at Washington University School of Medicine and Professor Rachel Green from Johns Hopkins University.Canopy Biosciences was formed in 2016 and is headquartered in Saint Louis, Missouri.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Apr 30, 2019 | Series Unknown | — | 1 | — | — | Detail |
May 22, 2018 | Series A | $2.40M | 6 | BioGenerator Kingdom Capital | — | Detail |
Jan 30, 2017 | Seed | $2M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
BioGenerator | Yes | Series A |
Kingdom Capital | Yes | Series A |
Ampersand Capital Partners | — | Series Unknown |
Greenleaf Seed Fund | — | Series A |
Archangels | — | Series A |
Missouri Technology Corporation | — | Series A |
Pinpoint Holdings | — | Series A |
Canopy Biosciences has acquired 2 organizations. Their most recent acquisition was Zellkraftwerk on Apr 29, 2019. They acquired Zellkraftwerk for 0.
Date
Company Name
|
Industry | Acquisition Type | Price | |
---|---|---|---|---|
Apr 29, 2019
Zellkraftwerk
|
Information Technology | acquisition | — | Detail |
Dec 6, 2019
Core Diagnostics
|
Biotechnology | acquisition | — | Detail |